As part of the agreement, the organizations will develop a joint Seattle-Shenzhen Institute.
The partners aim to establish and conduct programs and activities in agricultural research, technology, information transfer, and economic development.
BGI CEO Ye Yin says that mapping variation within the human genome will bring a "big data revolution" to healthcare, Wired UK writes.
BGI is seeking an IPO on a Shenzhen-based stock exchange, but the timing of when this might occur is unclear, FinanceAsia reports.
Several new laboratories started to offer NIPT locally in 2015, and some providers have been shifting to less-expensive non-NGS platforms.
Pacific Biosciences' launch of the Sequel instrument, Oxford Nanopore Technologies' MinIon instrument, and 10X Genomics' technology excited the market in 2015.
Only about 5 to 6 percent of women in China, mostly in urban areas, currently obtain NIPT, but their number is expected to increase quickly in coming years.
The partners will create, sequence, and characterize millions of new rice gene alleles, focusing on proprietary rice lines with high-density genome variation.
The company plans to lay off 145 employees at its Mountain View headquarters, as well as 15 in San Jose, 13 in Sunnyvale, and six in San Francisco.
Going forward, Complete Genomics will focus on clinical research and support BGI's noninvasive prenatal testing business as well as the launch of its benchtop sequencer in China.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.